The ‘totality-of-the-evidence’ approach in the development of PF-06438179/GP1111, an infliximab biosimilar, and in support of its use in all indications of the reference product...

by Joseph E. McClellan, Hugh D. Conlon, Michael W. Bolt, Vatche Kalfayan, Rameshraja Palaparthy, Muhammad I. Rehman, Carol F. Kirchhoff
Published 2019-06-01

A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthrit...

by Stanley B. Cohen, Rieke Alten, Hideto Kameda, Tomas Hala, Sebastiao C. Radominski, Muhammad I. Rehman, Ramesh Palaparthy, Karl Schumacher, Susanne Schmitt, Steven Y. Hua, Claudia Ianos, K. Lea Sewell
Published 2018-07-01